25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

XORTX Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Xortx together

I guess you are interested in XORTX Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of XORTX Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about XORTX Therapeutics Inc

I send you an email if I find something interesting about XORTX Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Xortx (30 sec.)










1.2. What can you expect buying and holding a share of Xortx? (30 sec.)

How much money do you get?

How much money do you get?
C$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
C$1.30
Expected worth in 1 year
C$-0.96
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
C$-2.25
Return On Investment
-114.5%

For what price can you sell your share?

Current Price per Share
C$1.97
Expected price per share
C$1.54 - C$3.65
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Xortx (5 min.)




Live pricePrice per Share (EOD)
C$1.97
Intrinsic Value Per Share
C$-25.25 - C$-29.57
Total Value Per Share
C$-23.95 - C$-28.27

2.2. Growth of Xortx (5 min.)




Is Xortx growing?

Current yearPrevious yearGrowGrow %
How rich?$2.7m$9.1m-$5.1m-130.0%

How much money is Xortx making?

Current yearPrevious yearGrowGrow %
Making money-$370.7k-$2m$1.6m439.8%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Xortx (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#743 / 958

Most Revenue
#848 / 958

Most Profit
#191 / 958

Most Efficient
#213 / 958
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Xortx?

Welcome investor! Xortx's management wants to use your money to grow the business. In return you get a share of Xortx.

First you should know what it really means to hold a share of Xortx. And how you can make/lose money.

Speculation

The Price per Share of Xortx is C$1.97. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Xortx.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Xortx, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is C$1.30. Based on the TTM, the Book Value Change Per Share is C$-0.56 per quarter. Based on the YOY, the Book Value Change Per Share is C$0.56 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is C$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Xortx.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 C$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per Share
Usd Eps0.063.0%-0.13-6.5%-0.38-19.4%-0.19-9.9%-0.19-9.9%
Usd Book Value Change Per Share0.073.7%-0.40-20.5%0.4020.4%0.063.2%0.063.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.073.7%-0.40-20.5%0.4020.4%0.063.2%0.063.2%
Usd Price Per Share1.84-3.13-7.00-5.61-5.61-
Price to Earnings Ratio7.86-1.21--9.04--4.26--4.26-
Price-to-Total Gains Ratio25.04-1.22--34.52--20.82--20.82-
Price to Book Ratio1.98-2.46-7.08-5.12-5.12-
Price-to-Total Gains Ratio25.04-1.22--34.52--20.82--20.82-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.412096
Number of shares708
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.400.06
Usd Total Gains Per Share-0.400.06
Gains per Quarter (708 shares)-286.0843.97
Gains per Year (708 shares)-1,144.30175.86
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1144-11540176166
20-2289-22980352342
30-3433-34420528518
40-4577-45860703694
50-5722-57300879870
60-6866-6874010551046
70-8010-8018012311222
80-9154-9162014071398
90-10299-10306015831574
100-11443-11450017591750

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%3.09.00.025.0%3.012.00.020.0%3.012.00.020.0%3.012.00.020.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.010.00.033.3%5.010.00.033.3%5.010.00.033.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.015.00.0%0.00.015.00.0%0.00.015.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.010.00.033.3%5.010.00.033.3%5.010.00.033.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of XORTX Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.103-0.564+649%0.560-82%0.087+18%0.087+18%
Book Value Per Share--1.2991.913-32%2.484-48%1.519-14%1.519-14%
Current Ratio--6.43510.836-41%10.842-41%10.334-38%10.334-38%
Debt To Asset Ratio--0.4360.315+39%0.208+110%0.397+10%0.397+10%
Debt To Equity Ratio--0.7740.618+25%0.322+141%0.545+42%0.545+42%
Dividend Per Share----0%-0%-0%-0%
Eps--0.082-0.178+318%-0.533+752%-0.272+433%-0.272+433%
Free Cash Flow Per Share---0.358-0.533+49%-0.663+85%-0.388+8%-0.388+8%
Free Cash Flow To Equity Per Share---0.362-0.369+2%-0.520+43%-0.133-63%-0.133-63%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---29.573--------
Intrinsic Value_10Y_min---25.252--------
Intrinsic Value_1Y_max---2.093--------
Intrinsic Value_1Y_min---2.055--------
Intrinsic Value_3Y_max---6.952--------
Intrinsic Value_3Y_min---6.623--------
Intrinsic Value_5Y_max---12.611--------
Intrinsic Value_5Y_min---11.648--------
Market Cap5720013.200-30%7462162.05012695825.563-41%97493059.215-92%81835992.358-91%81835992.358-91%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio1.516-30%1.9782.464-20%7.083-72%5.123-61%5.123-61%
Pe Ratio6.028-30%7.8631.205+552%-9.043+215%-4.257+154%-4.257+154%
Price Per Share1.970-30%2.5704.373-41%9.765-74%7.821-67%7.821-67%
Price To Free Cash Flow Ratio-1.375+23%-1.794-2.082+16%-9.336+421%-6.868+283%-6.868+283%
Price To Total Gains Ratio19.195-30%25.0421.221+1951%-34.525+238%-20.823+183%-20.823+183%
Quick Ratio--0.0440.116-62%0.059-25%0.082-47%0.082-47%
Return On Assets--0.035-0.043+220%-0.171+583%-0.152+530%-0.152+530%
Return On Equity--0.063-0.197+413%-0.221+452%-0.171+372%-0.171+372%
Total Gains Per Share--0.103-0.564+649%0.560-82%0.087+18%0.087+18%
Usd Book Value--2704560.8973980813.212-32%9156947.168-70%6582580.421-59%6582580.421-59%
Usd Book Value Change Per Share--0.074-0.404+649%0.401-82%0.062+18%0.062+18%
Usd Book Value Per Share--0.9311.371-32%1.780-48%1.089-14%1.089-14%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.059-0.128+318%-0.382+752%-0.195+433%-0.195+433%
Usd Free Cash Flow---745573.280-1109423.742+49%-2667400.525+258%-1682802.894+126%-1682802.894+126%
Usd Free Cash Flow Per Share---0.257-0.382+49%-0.476+85%-0.278+8%-0.278+8%
Usd Free Cash Flow To Equity Per Share---0.260-0.265+2%-0.373+43%-0.095-63%-0.095-63%
Usd Market Cap4100105.462-30%5348877.7579100367.763-41%69883024.845-92%58660039.322-91%58660039.322-91%
Usd Price Per Share1.412-30%1.8423.134-41%7.000-74%5.606-67%5.606-67%
Usd Profit--170055.116-370729.272+318%-2001023.426+1277%-1106412.585+751%-1106412.585+751%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--0.074-0.404+649%0.401-82%0.062+18%0.062+18%
 EOD+3 -5MRQTTM+17 -12YOY+13 -165Y+15 -1410Y+15 -14

3.3 Fundamental Score

Let's check the fundamental score of XORTX Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-156.028
Price to Book Ratio (EOD)Between0-11.516
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.044
Current Ratio (MRQ)Greater than16.435
Debt to Asset Ratio (MRQ)Less than10.436
Debt to Equity Ratio (MRQ)Less than10.774
Return on Equity (MRQ)Greater than0.150.063
Return on Assets (MRQ)Greater than0.050.035
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of XORTX Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.940
Ma 20Greater thanMa 502.272
Ma 50Greater thanMa 1002.328
Ma 100Greater thanMa 2002.381
OpenGreater thanClose2.000
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About XORTX Therapeutics Inc

XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.

Fundamental data was last updated by Penke on 2024-10-14 04:36:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Xortx earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Xortx to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of XORTX Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--135.4%+135.4%
TTM--201.5%+201.5%
YOY--209.8%+209.8%
5Y--359.0%+359.0%
10Y--472.9%+472.9%
4.3.1.2. Return on Assets

Shows how efficient Xortx is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Xortx to the Biotechnology industry mean.
  • 3.5% Return on Assets means that Xortx generated $0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of XORTX Therapeutics Inc:

  • The MRQ is 3.5%. Using its assets, the company is less efficient in making profit.
  • The TTM is -4.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ3.5%TTM-4.3%+7.8%
TTM-4.3%YOY-17.1%+12.9%
TTM-4.3%5Y-15.2%+11.0%
5Y-15.2%10Y-15.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5%-10.7%+14.2%
TTM-4.3%-11.7%+7.4%
YOY-17.1%-11.2%-5.9%
5Y-15.2%-12.6%-2.6%
10Y-15.2%-14.2%-1.0%
4.3.1.3. Return on Equity

Shows how efficient Xortx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Xortx to the Biotechnology industry mean.
  • 6.3% Return on Equity means Xortx generated $0.06 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of XORTX Therapeutics Inc:

  • The MRQ is 6.3%. Using its investors money, the company is less efficient in making profit.
  • The TTM is -19.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ6.3%TTM-19.7%+26.0%
TTM-19.7%YOY-22.1%+2.5%
TTM-19.7%5Y-17.1%-2.6%
5Y-17.1%10Y-17.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.3%-13.8%+20.1%
TTM-19.7%-16.0%-3.7%
YOY-22.1%-13.6%-8.5%
5Y-17.1%-18.5%+1.4%
10Y-17.1%-19.0%+1.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of XORTX Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Xortx is operating .

  • Measures how much profit Xortx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Xortx to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of XORTX Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--289.1%+289.1%
TTM--313.4%+313.4%
YOY--223.5%+223.5%
5Y--386.0%+386.0%
10Y--497.4%+497.4%
4.3.2.2. Operating Ratio

Measures how efficient Xortx is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of XORTX Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.821-2.821
TTM-3.146-3.146
YOY-3.336-3.336
5Y-4.839-4.839
10Y-6.520-6.520
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of XORTX Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Xortx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.43 means the company has $6.43 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of XORTX Therapeutics Inc:

  • The MRQ is 6.435. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.836. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.435TTM10.836-4.401
TTM10.836YOY10.842-0.006
TTM10.8365Y10.334+0.502
5Y10.33410Y10.3340.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4353.740+2.695
TTM10.8363.923+6.913
YOY10.8424.711+6.131
5Y10.3345.957+4.377
10Y10.3346.285+4.049
4.4.3.2. Quick Ratio

Measures if Xortx is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Xortx to the Biotechnology industry mean.
  • A Quick Ratio of 0.04 means the company can pay off $0.04 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of XORTX Therapeutics Inc:

  • The MRQ is 0.044. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.116. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.044TTM0.116-0.072
TTM0.116YOY0.059+0.057
TTM0.1165Y0.082+0.034
5Y0.08210Y0.0820.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0443.326-3.282
TTM0.1163.510-3.394
YOY0.0594.633-4.574
5Y0.0825.927-5.845
10Y0.0826.479-6.397
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of XORTX Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Xortx assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Xortx to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.44 means that Xortx assets are financed with 43.6% credit (debt) and the remaining percentage (100% - 43.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of XORTX Therapeutics Inc:

  • The MRQ is 0.436. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.315. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.436TTM0.315+0.122
TTM0.315YOY0.208+0.107
TTM0.3155Y0.397-0.083
5Y0.39710Y0.3970.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4360.339+0.097
TTM0.3150.347-0.032
YOY0.2080.310-0.102
5Y0.3970.365+0.032
10Y0.3970.381+0.016
4.5.4.2. Debt to Equity Ratio

Measures if Xortx is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Xortx to the Biotechnology industry mean.
  • A Debt to Equity ratio of 77.4% means that company has $0.77 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of XORTX Therapeutics Inc:

  • The MRQ is 0.774. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.618. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.774TTM0.618+0.156
TTM0.618YOY0.322+0.296
TTM0.6185Y0.545+0.073
5Y0.54510Y0.5450.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7740.393+0.381
TTM0.6180.444+0.174
YOY0.3220.375-0.053
5Y0.5450.450+0.095
10Y0.5450.489+0.056
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Xortx generates.

  • Above 15 is considered overpriced but always compare Xortx to the Biotechnology industry mean.
  • A PE ratio of 7.86 means the investor is paying $7.86 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of XORTX Therapeutics Inc:

  • The EOD is 6.028. Based on the earnings, the company is cheap. +2
  • The MRQ is 7.863. Based on the earnings, the company is underpriced. +1
  • The TTM is 1.205. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD6.028MRQ7.863-1.836
MRQ7.863TTM1.205+6.658
TTM1.205YOY-9.043+10.248
TTM1.2055Y-4.257+5.463
5Y-4.25710Y-4.2570.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.028-2.472+8.500
MRQ7.863-2.481+10.344
TTM1.205-2.977+4.182
YOY-9.043-3.435-5.608
5Y-4.257-5.847+1.590
10Y-4.257-6.262+2.005
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of XORTX Therapeutics Inc:

  • The EOD is -1.375. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.794. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.082. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.375MRQ-1.794+0.419
MRQ-1.794TTM-2.082+0.288
TTM-2.082YOY-9.336+7.254
TTM-2.0825Y-6.868+4.786
5Y-6.86810Y-6.8680.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.375-3.231+1.856
MRQ-1.794-3.261+1.467
TTM-2.082-3.497+1.415
YOY-9.336-4.550-4.786
5Y-6.868-7.975+1.107
10Y-6.868-8.686+1.818
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Xortx is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.98 means the investor is paying $1.98 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of XORTX Therapeutics Inc:

  • The EOD is 1.516. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.978. Based on the equity, the company is underpriced. +1
  • The TTM is 2.464. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.516MRQ1.978-0.462
MRQ1.978TTM2.464-0.486
TTM2.464YOY7.083-4.619
TTM2.4645Y5.123-2.659
5Y5.12310Y5.1230.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.5161.996-0.480
MRQ1.9781.985-0.007
TTM2.4642.191+0.273
YOY7.0832.387+4.696
5Y5.1233.580+1.543
10Y5.1234.199+0.924
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets4,799
Total Liabilities2,095
Total Stockholder Equity2,705
 As reported
Total Liabilities 2,095
Total Stockholder Equity+ 2,705
Total Assets = 4,799

Assets

Total Assets4,799
Total Current Assets3,357
Long-term Assets1,443
Total Current Assets
Cash And Cash Equivalents 3,078
Net Receivables 23
Total Current Assets  (as reported)3,357
Total Current Assets  (calculated)3,101
+/- 255
Long-term Assets
Property Plant Equipment 74
Intangible Assets 169
Long-term Assets  (as reported)1,443
Long-term Assets  (calculated)243
+/- 1,200

Liabilities & Shareholders' Equity

Total Current Liabilities522
Long-term Liabilities1,573
Total Stockholder Equity2,705
Total Current Liabilities
Accounts payable 270
Total Current Liabilities  (as reported)522
Total Current Liabilities  (calculated)270
+/- 252
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt84
Long-term Liabilities  (as reported)1,573
Long-term Liabilities  (calculated)84
+/- 1,489
Total Stockholder Equity
Total Stockholder Equity (as reported)2,705
Total Stockholder Equity (calculated)0
+/- 2,705
Other
Capital Stock17,871
Common Stock Shares Outstanding 2,904
Net Invested Capital 2,705
Net Working Capital 2,835
Property Plant and Equipment Gross 235



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-31
> Total Assets 
2,290
8,248
7,333
7,833
22,036
18,441
16,045
14,961
16,753
9,659
7,801
6,640
5,468
6,051
4,799
4,7996,0515,4686,6407,8019,65916,75314,96116,04518,44122,0367,8337,3338,2482,290
   > Total Current Assets 
2,056
8,018
7,097
7,589
20,173
16,580
14,014
12,951
14,750
8,213
6,378
5,226
4,069
4,662
3,357
3,3574,6624,0695,2266,3788,21314,75012,95114,01416,58020,1737,5897,0978,0182,056
       Cash And Cash Equivalents 
171
6,044
5,149
4,998
18,851
15,509
13,421
12,160
14,126
7,908
6,164
5,069
3,448
3,835
3,078
3,0783,8353,4485,0696,1647,90814,12612,16013,42115,50918,8514,9985,1496,044171
       Net Receivables 
14
11
23
22
52
156
249
87
111
36
30
68
61
31
23
233161683036111872491565222231114
       Other Current Assets 
1,826
1,826
1,826
2,448
0
220
0
615
0
0
0
0
0
0
0
0000000615022002,4481,8261,8261,826
   > Long-term Assets 
234
230
236
244
1,863
1,861
2,032
2,010
2,003
1,445
1,423
1,414
1,399
1,388
1,443
1,4431,3881,3991,4141,4231,4452,0032,0102,0321,8611,863244236230234
       Property Plant Equipment 
0
0
0
0
0
0
167
143
126
77
61
42
24
22
74
742224426177126143167000000
       Intangible Assets 
234
230
236
244
256
255
259
260
271
168
162
172
175
166
169
169166175172162168271260259255256244236230234
       Other Assets 
0
0
0
0
1,606
1,606
1,606
1,606
1,606
0
0
0
0
0
0
0000001,6061,6061,6061,6061,6060000
> Total Liabilities 
1,034
4,777
4,013
12,072
5,298
5,041
3,801
4,254
7,286
600
403
554
826
3,559
2,095
2,0953,5598265544036007,2864,2543,8015,0415,29812,0724,0134,7771,034
   > Total Current Liabilities 
1,034
4,777
4,013
12,072
701
856
995
1,944
2,050
600
403
554
295
341
522
5223412955544036002,0501,94499585670112,0724,0134,7771,034
       Accounts payable 
390
26
359
641
411
732
743
1,329
1,758
421
238
394
196
185
270
2701851963942384211,7581,32974373241164135926390
       Other Current Liabilities 
0
4,247
3,592
11,355
4,597
0
0
0
0
0
0
0
0
0
0
00000000004,59711,3553,5924,2470
   > Long-term Liabilities 
0
0
0
0
4,597
4,185
2,806
2,310
5,236
0
0
0
531
3,219
1,573
1,5733,2195310005,2362,3102,8064,1854,5970000
       Other Liabilities 
0
0
0
0
4,597
4,185
2,745
2,272
5,221
0
0
0
0
0
0
0000005,2212,2722,7454,1854,5970000
> Total Stockholder Equity
1,256
3,471
3,320
-4,239
16,738
13,401
12,244
10,707
9,466
9,059
7,398
6,086
4,642
2,491
2,705
2,7052,4914,6426,0867,3989,0599,46610,70712,24413,40116,738-4,2393,3203,4711,256
   Common Stock
8,258
12,278
12,255
13,057
20,009
20,009
20,009
20,009
20,607
0
0
0
0
0
0
00000020,60720,00920,00920,00920,00913,05712,25512,2788,258
   Retained Earnings -20,704-20,874-17,855-20,554-19,221-17,529-19,176-16,257-14,695-13,114-9,690-18,785-10,430-10,211-8,038
   Capital Surplus 000000000000000
   Treasury Stock000000000000000
   Other Stockholders Equity 
1,036
1,404
1,495
1,489
6,419
6,505
6,930
6,955
8,035
0
0
0
0
0
0
0000008,0356,9556,9306,5056,4191,4891,4951,4041,036



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-6,046
Operating Income-6,046-6,046
 
Operating Expense (+$)
Research Development2,419
Selling General Administrative2,228
Selling And Marketing Expenses-
Operating Expense6,0464,646
 
Net Interest Income (+$)
Interest Income255
Interest Expense--
Other Finance Cost-2
Net Interest Income254
 
Pretax Income (+$)
Operating Income-6,046
Net Interest Income254
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-2,158-9,680
EBIT - interestExpense = 0
-2,158
-2,158
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--2,158
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-2,158
Tax Provision--
Net Income From Continuing Ops-2,158-2,158
Net Income-2,158
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net3,634-254
 

Technical Analysis of Xortx
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Xortx. The general trend of Xortx is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Xortx's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of XORTX Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 3.3 < 3.46 < 3.65.

The bearish price targets are: 1.89 > 1.54.

Tweet this
XORTX Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of XORTX Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

XORTX Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of XORTX Therapeutics Inc. The current macd is -0.07800569.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Xortx price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Xortx. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Xortx price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
XORTX Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartXORTX Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of XORTX Therapeutics Inc. The current adx is 21.18.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Xortx shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
XORTX Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of XORTX Therapeutics Inc. The current sar is 3.2905168.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
XORTX Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of XORTX Therapeutics Inc. The current rsi is 40.94. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
XORTX Therapeutics Inc Daily Relative Strength Index (RSI) ChartXORTX Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of XORTX Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xortx price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
XORTX Therapeutics Inc Daily Stochastic Oscillator ChartXORTX Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of XORTX Therapeutics Inc. The current cci is -106.14510304.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
XORTX Therapeutics Inc Daily Commodity Channel Index (CCI) ChartXORTX Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of XORTX Therapeutics Inc. The current cmo is -29.1917583.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
XORTX Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartXORTX Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of XORTX Therapeutics Inc. The current willr is -94.30379747.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
XORTX Therapeutics Inc Daily Williams %R ChartXORTX Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of XORTX Therapeutics Inc.

XORTX Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of XORTX Therapeutics Inc. The current atr is 0.25234118.

XORTX Therapeutics Inc Daily Average True Range (ATR) ChartXORTX Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of XORTX Therapeutics Inc. The current obv is 535,361.

XORTX Therapeutics Inc Daily On-Balance Volume (OBV) ChartXORTX Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of XORTX Therapeutics Inc. The current mfi is 71.83.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
XORTX Therapeutics Inc Daily Money Flow Index (MFI) ChartXORTX Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for XORTX Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-13STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-07-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-11ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-13BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-28MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-05MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-10-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

XORTX Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of XORTX Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.940
Ma 20Greater thanMa 502.272
Ma 50Greater thanMa 1002.328
Ma 100Greater thanMa 2002.381
OpenGreater thanClose2.000
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Xortx with someone you think should read this too:
  • Are you bullish or bearish on Xortx? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Xortx? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about XORTX Therapeutics Inc

I send you an email if I find something interesting about XORTX Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about XORTX Therapeutics Inc.

Receive notifications about XORTX Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.